A cost‐effectiveness analysis of avelumab plus best supportive care versus best supportive care alone as first‐line maintenance treatment for patients with locally advanced or metastatic urothelial carcinoma in Taiwan
Po‐Jung Su,
Ying Xiao,
Amy Y. Lin
et al.
Abstract:BackgroundPatients with locally advanced or metastatic urothelial carcinoma have limited treatment options and a poor prognosis. The JAVELIN Bladder 100 trial showed that avelumab as first‐line maintenance plus best supportive care significantly prolonged overall survival and progression‐free survival versus best supportive care alone in patients with locally advanced or metastatic urothelial carcinoma that had not progressed with first‐line platinum‐containing chemotherapy.AimsWe assessed whether avelumab plu… Show more
Set email alert for when this publication receives citations?
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.